Laurus Labs Ltd News

Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 observations and adverse outcomes

Nifty Midcap index dips below 200-DMA; remain on sidelines, analysts advise

The breach of a critical level after a period of nearly 10 months reflects a shift in sentiment. The overall trend remains bearish as the index is making lower top, lower bottom on the technical chart

Laurus Labs slips 5%, hits over 2-year low post December quarter results

Laurus Labs delivered operationally in-line performance, led by healthy traction in CDMO-Synthesis/Non-ARV API segment

Beside Adani Green, Adani Transmission; 14 other stocks hit new 52-week low

Whenever a stock hits a new 52-week low, further fall from a medium-term scale appears realistic, with price endorsing further correction of 10 per cent to 12 per cent.

Mehul Kothari recommends to buy Laurus Labs, RateGain Travel Technologies

According to the technical analyst from Anand Rathi, Laurus Labs can rally to Rs 400; while RateGain can jump to Rs 330.

Laurus Labs hits 52-week low, tanks 7% on margin concerns

Laurus has witnessed severe pricing pressure and lower volumes in its ARV formulations portfolio for five quarters now, resulting in significant pressure on core margins, say analyst.

Laurus Labs hits 4-month low; stock slips 14% in 3 days post mixed Q2FY23

Despite mixed Q2FY23 performance, brokerages retain their 'buy' rating on Laurus Labs with a target price in the range of Rs 610 and Rs 630 per share.